Skip to main content

Advertisement

Table 1 Patient characteristics in study groups at inclusion in the study (before) and after 12 weeks of treatment (after) with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET), empagliflozin/metformin (EMPA/MET) or placebo (PLACEBO)

From: Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus

  PLACEBO EMPA MET EMPA/MET
Before After Before After Before After Before After
Average age (years) 43.1 ± 2.1 46.0 ± 2.3 46.4 ± 3.9 43.3 ± 2.6
Duration of diabetes (years) 22.2 ± 3.8 22.5 ± 3.7 23.2 ± 4.8 22.3 ± 3.2
HbA1c (%) 7.8 ± 0.2 7.7 ± 0.3 7.8 ± 0.1 7.4 ± 0.1 7.9 ± 0.2 7.7 ± 0.3 7.8 ± 0.2 7.2 ± 0.2*
Systolic BP (mmHg) 129.9 ± 4.0 127.4 ± 2.9 134.5 ± 3.0 127.2 ± 2.9 132.4 ± 3.1 125.9 ± 2.1 129.9 ± 2.6 124.8 ± 3.4
Diastolic BP (mmHg) 73.2 ± 5.4 77.0 ± 2.4 83.8 ± 2.6 81.9 ± 2.4 79.1 ± 1.5 79.8 ± 2.3 84.4 ± 1.1 73.7 ± 1.8
BMI (kg/m2) 28.3 ± 0.5 28.5 ± 0.31 28.9 ± 0.7 28.4 ± 0.6 28.0 ± 0.3 27.5 ± 0.3 28.9 ± 0.9 27.7 ± 1.0
Waist circumference (cm) 96.9 ± 3.9 95.2 ± 3.5 101.4 ± 2.9 97.1 ± 2.6 97.8 ± 4.0 97.9 ± 4.9 99.1 ± 3.9 97.7 ± 3.6
  1. Values are expressed as mean ± standard error of the means
  2. BP, blood pressure; BMI, body mass index; HbA1c, glycated haemoglobin
  3. * P < 0.05 for comparison within the group